Fortress Biotech Inc (FBIO)

Mar 31, 2025, 4:05 PM EDT - 26 days ago

Fortress Biotech Reports 2024 Financial Results and Recent Corporate Highlights

Mar 28, 2025, 8:30 AM EDT - 4 weeks ago

Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates

Mar 26, 2025, 7:39 PM EDT - 4 weeks ago

Fortress Biotech, Inc. (FBIO) Q4 2024 Earnings Call Transcript

Mar 26, 2025, 4:01 PM EDT - 4 weeks ago

Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights

Mar 24, 2025, 8:30 AM EDT - 4 weeks ago

Journey Medical Corporation Launches Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the Treatment of Rosacea

Mar 19, 2025, 4:01 PM EDT - 5 weeks ago

Journey Medical Corporation to Announce Year End 2024 Financial Results on March 26, 2025

Mar 17, 2025, 8:55 AM EDT - 5 weeks ago

Partex and Fortress Biotech Announce Strategic Collaboration to Accelerate Asset Identification and Evaluation Using Proprietary AI Platform

Mar 12, 2025, 8:30 AM EDT - 6 weeks ago

Journey Medical Corporation to Participate in the 37th Annual ROTH Conference

Mar 9, 2025, 10:06 PM EDT - 6 weeks ago

Sun Pharma to Acquire Checkpoint Therapeutics

Mar 5, 2025, 4:15 PM EST - 7 weeks ago

Mustang Bio Regains Compliance with Nasdaq Capital Market Requirement

MBIO

Mar 5, 2025, 4:01 PM EST - 7 weeks ago

Journey Medical Corporation Announces Publication in the Journal of the American Medical Association - Dermatology of the Phase 3 Clinical Trial Results of Emrosi™ (DFD-29) to Treat Rosacea

Mar 4, 2025, 4:01 PM EST - 7 weeks ago

Journey Medical Corporation to Exhibit at the 2025 American Academy of Dermatology Annual Meeting in Orlando, Florida

Jan 27, 2025, 8:30 AM EST - 3 months ago

Fortress Biotech Announces First Patient Dosed in Phase 2 Clinical Trial of Triplex Vaccination in Stem Cell Donors to Reduce CMV Events in Recipients of HSCT

Jan 23, 2025, 8:30 AM EST - 3 months ago

Journey Medical Corporation to Host Conference Call to Discuss U.S. Commercial Launch Plan for Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea

Jan 6, 2025, 8:00 AM EST - 3 months ago

Sentynl Therapeutics Announces U.S. FDA Acceptance and Priority Review of New Drug Application for CUTX-101 (Copper Histidinate) Product Candidate for Treatment of Menkes Disease

Jan 6, 2025, 8:00 AM EST - 3 months ago

Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Acceptance and Priority Review of NDA for CUTX-101 for Treatment of Menkes Disease

Dec 13, 2024, 6:15 PM EST - 4 months ago

Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl)

Nov 14, 2024, 4:10 PM EST - 5 months ago

Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

Nov 12, 2024, 4:30 PM EST - 5 months ago

Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates

Nov 12, 2024, 4:01 PM EST - 5 months ago

Journey Medical Corporation Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

Nov 4, 2024, 7:00 AM EST - 6 months ago

Journey Medical Corporation Announces U.S. FDA Approval of Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea

Oct 25, 2024, 8:30 AM EDT - 6 months ago

Journey Medical Corporation Announces DFD-29 Data Presented at 44th Fall Clinical Dermatology Conference

Oct 3, 2024, 8:30 AM EDT - 7 months ago

Journey Medical Corporation to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

Sep 26, 2024, 8:30 AM EDT - 7 months ago

Fortress Biotech to Participate in October 2024 Investor Conferences

Sep 20, 2024, 8:30 AM EDT - 7 months ago

Fortress Biotech Announces Pricing of $8 Million Registered Direct Offering and Concurrent Private Placements

Sep 16, 2024, 7:30 AM EDT - 7 months ago

Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 2024

Sep 9, 2024, 8:30 AM EDT - 8 months ago

Journey Medical Corporation to Participate in the Lake Street Capital Markets 8th Annual Best Ideas Growth (BIG) Conference

Sep 4, 2024, 8:30 AM EDT - 8 months ago

Fortress Biotech to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 4, 2024, 8:15 AM EDT - 8 months ago

Journey Medical Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 4, 2024, 8:00 AM EDT - 8 months ago

Checkpoint Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

Aug 13, 2024, 4:05 PM EDT - 9 months ago

Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

Aug 12, 2024, 4:01 PM EDT - 9 months ago

Journey Medical Corporation Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

Aug 12, 2024, 8:30 AM EDT - 9 months ago

Checkpoint Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Updates

Aug 6, 2024, 4:01 PM EDT - 9 months ago

Journey Medical Corporation to Announce Second Quarter 2024 Financial Results on August 12, 2024

Jul 25, 2024, 8:30 AM EDT - 9 months ago

Fortress Biotech Reduces Total Debt and Enters into New $35 Million Term Loan with Oaktree with Maturity in 2027

Jul 25, 2024, 7:30 AM EDT - 9 months ago

Checkpoint Therapeutics Announces FDA Acceptance of BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma

Jul 15, 2024, 8:00 AM EDT - 10 months ago

GC Cell and Checkpoint Therapeutics Advance Collaborative Cancer Research

Jul 11, 2024, 4:05 PM EDT - 10 months ago

Journey Medical Corporation Appoints Michael C. Pearce to Board of Directors

Jul 5, 2024, 4:05 PM EDT - 10 months ago

Fortress Biotech Announces Pause in Payment of Dividends on 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock

Jul 2, 2024, 8:00 AM EDT - 10 months ago

Checkpoint Therapeutics Announces $12 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jul 2, 2024, 7:00 AM EDT - 10 months ago

Checkpoint Therapeutics Announces Biologics License Application Resubmission for Cosibelimab

Jun 24, 2024, 7:30 AM EDT - 10 months ago

Checkpoint Therapeutics Announces Alignment with FDA Enabling Upcoming Cosibelimab BLA Resubmission

May 16, 2024, 8:00 AM EDT - 1 year ago

Fortress Biotech to Participate in the Alliance Global Partners' (A.G.P.) Virtual Healthcare Company Showcase

May 15, 2024, 4:15 PM EDT - 1 year ago

Fortress Biotech Reports First Quarter 2024 Financial Results and Recent Corporate Highlights

May 15, 2024, 4:01 PM EDT - 1 year ago

Journey Medical Corporation to Participate in the Alliance Global Partners' (A.G.P.) Virtual Healthcare Company Showcase

May 14, 2024, 8:30 AM EDT - 1 year ago

Fortress Biotech Announces First Patient Dosed in Multi-Center Phase 2 Study of Triplex for Control of CMV in Patients Undergoing Liver Transplantation

May 13, 2024, 4:01 PM EDT - 1 year ago

Journey Medical Corporation Reports First Quarter 2024 Financial Results and Recent Corporate Highlights

May 13, 2024, 8:30 AM EDT - 1 year ago

Checkpoint Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference